LEIDEN, NETHERLANDS, March 24, 2026
Pharming Group has announced that Japan’s Ministry of Health, Labour and Welfare has approved Joenja (leniolisib), an oral selective PI3K delta inhibitor, for the treatment of Activated PI3K Delta Syndrome (APDS) in adult and pediatric patients aged 4 years and older. This landmark approval marks the first targeted therapy available in Japan for APDS and represents a significant advancement in treating this rare and progressive immune disorder, particularly for younger pediatric populations.
First Targeted Therapy for Rare APDS in Japan
The approval of Joenja introduces a novel precision medicine approach for APDS, a rare primary immunodeficiency caused by genetic mutations affecting immune cell function. Until now, patients in Japan have relied largely on supportive care and symptom management, highlighting the importance of this regulatory milestone.
Joenja is the first and only targeted treatment specifically approved for APDS in Japan, addressing the underlying disease mechanism rather than just symptoms. Notably, this approval also represents the first global authorization for children aged 4 to 11 years, significantly expanding treatment access for pediatric patients suffering from this debilitating condition.
Experts emphasize that APDS patients often experience delayed diagnosis and progressive disease complications, including recurrent infections, lymphoproliferation, and immune dysregulation. The introduction of Joenja is expected to reduce disease burden and improve long-term clinical outcomes for patients and families impacted by this rare disorder.
Advertisement
Strong Phase III Data Supports Regulatory Approval
The Japanese approval of Joenja is supported by robust Phase III clinical trial data, including multinational and Japan-specific studies. In these trials, leniolisib demonstrated statistically significant improvements in key clinical endpoints, including reduction in lymphadenopathy and increased levels of naïve B cells, which are critical indicators of immune system function.
These findings highlight Joenja’s ability to address immune dysregulation at a molecular level, providing meaningful therapeutic benefits beyond conventional treatment approaches. Additionally, the drug was shown to be generally well tolerated, with the most common adverse events including headache, sinusitis, and atopic dermatitis.
Further supporting evidence from pediatric studies confirmed clinical improvements in children aged 4 to 11 years, reinforcing the therapy’s potential to deliver consistent benefits across age groups. The approval was granted under Japan’s Priority Review pathway, reflecting the urgent unmet medical need in APDS treatment and the therapy’s strong clinical profile.
Expanding Global Access and Commercial Strategy
Joenja is already approved in major markets including the United States and the United Kingdom for patients aged 12 years and older, and this latest approval strengthens Pharming’s global commercialization strategy. In Japan, the product will be marketed in partnership with OrphanPacific, which will support distribution and patient access following pricing agreements with national health authorities.
The therapy’s mechanism of action involves inhibition of the PI3K delta pathway, a key regulator of immune cell activity. By targeting this pathway, Joenja helps restore immune balance, offering a disease-modifying approach for APDS patients.
With ongoing regulatory reviews in Europe, Canada, and other regions, as well as continued clinical development in related immune disorders, Pharming is positioning Joenja as a cornerstone therapy in rare immunology. This approval underscores the company’s commitment to advancing innovative treatments for rare diseases with high unmet need.
Source: Pharming Group press release
